Related Experiment Videos
Potential anticancer agents. XXIII. 1. Qualitative structure--activity relationship in the "classical" antifolates
Neoplasma
|January 1, 1982
Summary
Researchers synthesized novel antifolate analogs to improve therapeutic index. One analog, compound 16, showed enhanced potency against dihydrofolate reductase (DHFR) and potential for treating methotrexate-resistant cancers due to increased hydrophobicity.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Classical antifolates, like Methotrexate (MTX), are crucial in cancer therapy.
- Improving the therapeutic index of antifolates is essential for enhanced treatment efficacy.
- Understanding structure-activity relationships (SAR) guides the development of novel drug candidates.
Purpose of the Study:
- To synthesize and evaluate novel Methotrexate analogues for improved anticancer activity.
- To investigate the SAR of these analogues to identify key structural features for enhanced efficacy.
- To explore potential candidates for overcoming MTX resistance in cancer cells.
Main Methods:
- Synthesis of 32 novel Methotrexate analogues.
- Structure-activity relationship analysis of the synthesized compounds.
- Evaluation of inhibitory activity against dihydrofolate reductase (DHFR).
- Assessment of cytotoxic activity against L1210 leukemia cell lines and experimental tumors.
Main Results:
- Replacement of the glutamyl moiety with other amino acids yielded potent DHFR inhibitors but lacked activity against L1210 leukemia.
- Methoxy group substitution on the phenyl ring resulted in potent DHFR inhibitors with activity against experimental tumors.
- Insertion of an additional amino acid in the side chain negatively impacted compound activity.
- MTX analogues with side chains at the C7 position of the pteridine ring were ineffective.
- Compound 16, a specific analogue, demonstrated twofold greater potency against DHFR than MTX and exhibited increased hydrophobicity.
Conclusions:
- Structural modifications significantly influence the activity of antifolates.
- Methoxy substitutions and specific side chain designs can lead to potent DHFR inhibitors with anticancer activity.
- Compound 16 presents a promising candidate for treating MTX-resistant cancers due to its enhanced DHFR inhibition and hydrophobicity, potentially overcoming transport-related resistance mechanisms.